Susvimo has the same active ingredient as Roche's big-selling therapy Lucentis (ranibizumab), a VEGF inhibitor administered once a month that has been approved by the FDA since 2006 for wet AMD.

Roche is to buy gene therapy firm Spark Therapeutics for $4.8 billion, adding an already-approved treatment for inherited blindness to its portfolio, and boosting its pipeline with a series of ...

European Commission President Ursula von der Leyen held a call with metals industry representatives on Monday and was due to speak later to the automobile sector about how to respond to U.S. tariffs.